Mylan Laboratories Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Mylan Laboratories Limited Pharmaceutical Export Portfolio Dataset — 91 Products, $634.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan Laboratories Limited — Pharmaceutical Exporter Profile (2026) | 91 Products, $634.8M Trade | TransData Nexus

Mylan Laboratories Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $634.8M Total Trade · DGFT Verified

Mylan Laboratories Limited is an Indian pharmaceutical exporter with a total trade value of $634.8M across 91 products in 26 therapeutic categories. Based on 13,583 verified export shipments from Indian Customs (DGFT) records, Mylan Laboratories Limited is the #1 Indian exporter in 23 products including Pantoprazole, Valsartan, Trastuzumab. Top exports include Tenofovir ($50.1M), Pantoprazole ($33.0M), Valsartan ($28.9M).

Mylan Laboratories Limited — Export Portfolio & Destination Treemap

Mylan Laboratories Limited pharmaceutical export portfolio — 91 products across 26 therapeutic categories. Source: Indian Customs (DGFT).

Who is Mylan Laboratories Limited? — Company Overview & Market Position

Mylan Laboratories Limited, incorporated on November 29, 1984, is a prominent Indian pharmaceutical company specializing in the manufacture of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is registered under the Corporate Identification Number (CIN) U24231TG1984PLC005146 and is headquartered in Hyderabad, Telangana, India.

As of March 31, 2023, Mylan Laboratories Limited reported an authorized share capital of ₹1,250,000,000 and a paid-up capital of ₹487,025,270. The company is privately held and operates as a non-government entity. While specific revenue figures are not publicly disclosed, Mylan Laboratories Limited is recognized as a significant player in the Indian pharmaceutical export sector.

What Does Mylan Laboratories Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Tenofovir$50.1M 2Pantoprazole$33.0M

Product Portfolio — Top 30 by Export Value

Mylan Laboratories Limited exports 91 pharmaceutical products across 26 therapeutic categories. Market leader (#1 exporter) in 23 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Tenofovir	Antiviral & HIV Medications	$50.1M	1,002	1.2%	3
2	Pantoprazole	Gastrointestinal	$33.0M	661	2.5%	1
3	Valsartan	Cardiovascular	$28.9M	578	14.7%	1
4	Ritonavir	Antiviral & HIV Medications	$27.5M	550	8.1%	2
5	Trastuzumab	Advanced Oncology	$25.1M	503	32.6%	1
6	Lansoprazole	Gastrointestinal	$20.8M	416	7.2%	2
7	Ras	Ayurvedic & Herbal Products	$20.1M	402	6.5%	3
8	Amlodipine	Cardiovascular	$19.4M	387	0.2%	3
9	Atorvastatin	Cardiovascular	$16.5M	330	1.5%	3
10	Hydrochlorothiazide	Diuretics	$16.4M	329	4.0%	3
11	Ramipril	Cardiovascular	$16.0M	320	17.8%	1
12	Vancomycin	Antibiotics	$15.9M	319	17.3%	1
13	Metoprolol	Cardiovascular	$14.2M	283	1.7%	4
14	Darunavir	Antiviral & HIV Medications	$13.4M	269	22.2%	3
15	Emtricitabine	Antiviral & HIV Medications	$13.3M	265	11.1%	1
16	Simvastatin	Cardiovascular	$13.3M	265	10.5%	1
17	Calcium	Vitamins & Supplements	$13.2M	264	1.5%	2
18	Rosuvastatin	Cardiovascular	$13.0M	621	2.8%	10
19	Rivaroxaban	Cardiovascular	$12.8M	257	24.4%	1
20	Ezetimibe	Lipid & Metabolism	$12.3M	246	2.4%	4
21	Telmisartan	Cardiovascular	$12.0M	240	0.1%	2
22	Atazanavir	Antiviral & HIV Medications	$11.3M	226	15.9%	1
23	Irbesartan	Cardiovascular	$10.8M	217	10.2%	2
24	Citalopram	CNS & Psychiatric	$10.1M	202	4.0%	5
25	Sofosbuvir	Antiviral & HIV Medications	$9.9M	199	24.3%	1
26	Ibuprofen	Analgesics & Antipyretics	$9.2M	184	1.6%	1
27	Esomeprazole	Gastrointestinal	$8.9M	179	2.0%	3
28	Efavirenz	Antivirals	$8.3M	167	13.9%	2
29	Famotidine	Gastrointestinal	$7.5M	212	13.5%	3
30	Sodium	Nutritional Supplements	$7.5M	150	2.1%	7

Mylan Laboratories Limited exports 91 pharmaceutical products across 26 therapeutic categories with a total export value of $634.8M. The company is the #1 Indian exporter in 23 products: Pantoprazole, Valsartan, Trastuzumab, Ramipril, Vancomycin and 6 more. The top category is Cardiovascular (28.4% of portfolio), followed by Antiviral & HIV Medications (21.2%), reflecting a diversified portfolio where the top 5 products account for only 25.9% of total value.

Showing top 30 of 91 products. Contact us for complete data.

Mylan Laboratories Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Mylan Laboratories Limited operates multiple manufacturing facilities across India, strategically located to serve both domestic and international markets. These facilities are equipped to produce a wide range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's manufacturing plants adhere to stringent quality standards, ensuring the production of high-quality pharmaceutical products. Specific details regarding the capacities and specializations of each facility are proprietary and not publicly disclosed.

3Key Leadership

The leadership team at Mylan Laboratories Limited comprises experienced professionals dedicated to steering the company's strategic direction and operational excellence. The Board of Directors includes:

Rajiv Malik
Nagaraj Goud Bodige
Rajiv Krishan Luthra
Mohit Saraf
Sarada Kalyani Bhagawati
Rakesh Bamzai

These individuals bring a wealth of expertise in pharmaceuticals, business management, and regulatory affairs, contributing to the company's growth and compliance with international standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Mylan Laboratories Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Mylan Laboratories Limited has established a robust presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA), facilitating the marketing of its generic pharmaceutical products in the U.S. market. Additionally, Mylan Laboratories Limited has obtained European Union Good Manufacturing Practice (EU GMP) certificates, ensuring compliance with EU standards for pharmaceutical manufacturing. The company's products are also registered with the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the Therapeutic Goods Administration (TGA) in Australia, and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, demonstrating its commitment to meeting the regulatory requirements of these markets.

2Emerging Markets

Mylan Laboratories Limited has strategically expanded its footprint in emerging markets across Africa, Latin America, and Southeast Asia. The company's products are prequalified by the World Health Organization (WHO), enabling access to these regions and reinforcing its commitment to providing quality medicines globally. This prequalification facilitates the procurement of Mylan's products by international organizations and governments, enhancing the company's reach in underserved markets. (extranet.who.int)

Mylan Laboratories Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Mylan Laboratories Limited's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), allowing the company to market its pharmaceutical products in the United States. The company has filed numerous Abbreviated New Drug Applications (ANDAs), facilitating the approval of its generic products in the U.S. market. However, in August 2020, the FDA issued a warning letter to Mylan Laboratories Limited's Unit 7 facility in Pashamylaram, India, citing deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (APIs). The FDA identified issues related to data integrity and testing on packaging materials, among others. Mylan Laboratories Limited has since implemented remediation plans to address these concerns and is working closely with the FDA to ensure compliance.

2WHO & EU GMP

Mylan Laboratories Limited's manufacturing facilities have been inspected and certified by the World Health Organization (WHO) and the European Union (EU) for Good Manufacturing Practice (GMP). The company's Indore facility in Pithampur, Madhya Pradesh, India, underwent a WHO prequalification inspection in March 2025. The inspection identified areas for improvement, particularly concerning data integrity and stability sample testing. Mylan Laboratories Limited is actively addressing these issues to maintain the quality and safety of its products. (extranet.who.int)

Mylan Laboratories Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Mylan Laboratories Limited operates in a competitive landscape, facing competition from both domestic and international pharmaceutical companies. Key competitors include other Indian pharmaceutical exporters and multinational corporations with a presence in the generic drug market. The company's focus on obtaining regulatory approvals and certifications in various markets enhances its competitiveness. Additionally, Mylan Laboratories Limited's commitment to quality and compliance with international standards positions it favorably in the global pharmaceutical industry.

2Key Differentiators

Mylan Laboratories Limited's key differentiators include its extensive product portfolio, encompassing 91 products across 26 therapeutic categories, and its leadership in several key products such as Pantoprazole, Valsartan, and Trastuzumab. The company's manufacturing facilities are certified by WHO and EU GMP, ensuring adherence to international quality standards. Mylan Laboratories Limited's strategic geographic diversification and focus on obtaining regulatory approvals in various markets further distinguish it in the pharmaceutical industry.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Mylan Laboratories Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Mylan Laboratories Limited has a track record of consistent export volume, with a total export value of $634.8 million USD and 13,583 shipments across 91 products. The company's adherence to international quality standards, as evidenced by its WHO and EU GMP certifications, indicates reliability in product quality. While the FDA warning letter in August 2020 raised concerns, Mylan Laboratories Limited has taken corrective actions to address the identified issues, demonstrating a commitment to continuous improvement and compliance.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Facility Registration: Confirm the facility's registration status with the FDA to ensure eligibility for exporting to the U.S. market.

WHO-GMP Certification: Verify the WHO-GMP certification to ensure adherence to international manufacturing standards.

Frequently Asked Questions — Mylan Laboratories Limited

How many pharmaceutical products does Mylan Laboratories Limited export from India?

Mylan Laboratories Limited exports 91 pharmaceutical products across 26 therapeutic categories. The top exports are Tenofovir ($50.1M), Pantoprazole ($33.0M), Valsartan ($28.9M), Ritonavir ($27.5M), Trastuzumab ($25.1M). Total export value is $634.8M.

What is Mylan Laboratories Limited's total pharmaceutical export value?

Mylan Laboratories Limited's total pharmaceutical export value is $634.8M, based on 13,583 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Mylan Laboratories Limited the #1 Indian exporter?

Mylan Laboratories Limited is the #1 Indian exporter in 23 products: Pantoprazole (2.5% market share), Valsartan (14.7% market share), Trastuzumab (32.6% market share), Ramipril (17.8% market share), Vancomycin (17.3% market share), Emtricitabine (11.1% market share), Simvastatin (10.5% market share), Rivaroxaban (24.4% market share), Atazanavir (15.9% market share), Sofosbuvir (24.3% market share), Ibuprofen (1.6% market share).

What therapeutic categories does Mylan Laboratories Limited cover?

Mylan Laboratories Limited exports across 26 therapeutic categories. The largest are Cardiovascular (28.4%, 19 products), Antiviral & HIV Medications (21.2%, 9 products), Gastrointestinal (12.2%, 6 products).

Get Full Mylan Laboratories Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.